XPF-001

Xenon Pharmaceuticals Inc. · Phase 2 active Small molecule

At a glance

Generic name	XPF-001
Sponsor	Xenon Pharmaceuticals Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction (PHASE2)
Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) (PHASE1, PHASE2)
Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XPF-001 CI brief — competitive landscape report
XPF-001 updates RSS · CI watch RSS
Xenon Pharmaceuticals Inc. portfolio CI